First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
value - The stock trades at 1.5x sales and 1.3x book with 10.5% FCF yield despite -35% one-year return…
Rising rates moderately impact Teleflex through higher borrowing costs on its $3.5B debt (0.72 D/E ratio)…
Watch on earnings: Monthly UroLift procedure volumes reported by CMS and commercial claims data, Hospital admissions and surgical procedure volumes (AHA statistics, CMS data) as leading indicators for device utilization, FDA 510(k) clearance pipeline and competitive product approvals in vascular access and interventional urology.
One Sentence Summary:
Teleflex: the story is balanced — urolift procedure volume growth and reimbursement coverage expansion (medicare, commercial payers).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.